Clear, comprehensive and insightful talk by Terry Friedlander Terry Friedlander at #ESMOASIA2023 highlighting exciting new advances in mUC!

I can’t agree more and would like to add that I hope it can be available for all eligible 1L mUC patients worldwide!

How did Covid impact our international fellows?Carlos Stecca Princess Margaret Cancer Centre sciencedirect.com/science/articl…

I knew this would happen ! And it happened on stage…..my 1st “Terrible Towel”!

Great summary of contemporary treatment algorithms for patients presenting with metastatic UC by Dr. Srikala Sridhar Princess Margaret Cancer Centre #ASCO2022 #bladdercancer

Great news!! Thank you to all the patients and their families who help make these important advances happen! Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer prn.to/3o0YyPJ Princess Margaret Cancer Centre BladderCancerCanada

The BISCAY trial explored durvalumab with PARPi, FGFRi or TORC1/2i in biomarker selected patients with UC. A big team effort. The combos did not appear synergistic and responses lacked durability. ctDNA analysis showed dynamic changes with response. nature.com/articles/s4159…

I couldn't agree more! This is indeed great news, but access to these novel therapies remains a significant challenge in many places in the world.

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer | ⁦OncoAlert⁩ ⁦Prostate Cancer Foundation⁩ ⁦PCF Science⁩ ⁦Dana-Farber Lank Center for Genitourinary Oncology⁩ ⁦Novartis⁩ novartis.com/news/media-rel…

Sharing some thoughts about the differences between managing and leading in academic medicine. Thanks for reading.

On managing and leading by Mark Robson onservice.substack.com/p/on-managing-…

Algorithm Proposed to Expand Cisplatin Eligibility for MIBC ow.ly/Fpas50DHFZP #blcsm #kidney

This is where #PROOF302 comes in. With infigratinib (a potent & specific FGFR3i), we plan to enroll FGFR3m pts (seen at higher rate in #UTUC ) who (based on work from Dr. Bishoy M. Faltas) may have an immune-depleted phenotype. This #SUO -led study is enrolling now internationally. (7/9)

Multidisciplinary collaborations are the key to move the field of penile cancer forward. Check out our recent publication! rdcu.be/cdH2b Carlos Stecca Maria Jiang Girish Kulkarni Princess Margaret Cancer Centre University Health Network

I totally agree. Petros, please accept my deepest sympathies during this very difficult time for you and your family.Petros Grivas

Great news for our Canadian patients with advanced urothelial cancer and disease that has responded to first- line platinum based chemotherapy!@BladderCancerCA Tom Powles Petros Grivas Pfizer Inc. EMD Serono

[Thread 1 of 3]
Happy to be part in a series of podcasts on key controversies in #prostatecancer hosted by @uromigos Tom Powles and Brian Rini, MD

Episode 1, Jan 8, Oligometastatic Disease, featuring
Piet Ost Christopher Sweeney, MBBS silke gillessen

Links & info in following threads👇

Thank you to UroToday.com and Dr. Morgans Alicia Morgans, MD, MPH for highlighting the importance of biomarker work in the #Javelin Bladder 100 trial! Tom Powles Petros Grivas Princess Margaret Cancer Centre

Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat mCRPC. Maria Jiang Nazanin Fallah-Rad Princess Margaret Cancer Centre University Health Network Shilpa Gupta sciencedirect.com/science/articl…

Great start IBCN meeting with greetings from the board Ashish M. Kamat, MD, MBBS Peter Goebel Peter Black Roland Seiler-Blarer Stephen B. Williams, MD, MBA, MS, FACHE Tilman Todenhöfer & others! We need more ladies on the board for diversity :-) awesome to see you all! OncoAlert IBCG Bladder Cancer Advocacy Network Shilpa Gupta

Dr. Srikala Sridhar KSridhar, Dr. Sebastien Hotte Sebastien Hotte and Dr. Petros Grivas Petros Grivas discuss the key #GUCancer trials from #ESMO20 in this roundtable video: ow.ly/c8Ib30rd3CM